队列
质子
辐照
质子疗法
医学
核医学
肿瘤科
内科学
放射治疗
物理
核物理学
作者
Alonso La Rosa,Zachary T. Fellows,Andrew J. Wroe,Len Coutinho,Eduardo Pons,Nicole C. McAllister,Ranjini Tolakanahalli,Tuğçe Kütük,Matthew D. Hall,Robert H. Press,Michael William McDermott,Yazmín Odia,Manmeet Singh Ahluwalia,Minesh P. Mehta,Alonso N. Gutiérrez,Rupesh R Kotecha
标识
DOI:10.1038/s41598-024-78370-x
摘要
Recurrent high-grade intracranial malignancies have a grim prognosis and uniform management guidelines are lacking. Re-irradiation is underused due to concerns about irreversible side effects. Pulsed-reduced dose rate radiotherapy (PRDR) aims to reduce toxicity while improving tumor control by exploiting dose-rate effects. We share our initial experience with temporally modulated pulsed proton re-irradiation (TMPPR), focusing on workflow, safety, feasibility, and outcomes for the first patient cohort. TMPPR was administered to patients with recurrent or progressive central nervous system malignancies using intensity modulated proton therapy with three fields. Patient and treatment data were collected, responses categorized using RANO assessment, and toxicities graded using CTCAE v5.0. Five patients received TMPPR between October 2022 and May 2023, with a median age of 54 years (Range: 32-72), and a median time from initial radiotherapy to re-RT of 23 months (Range 14-40). Treatment was completed without delay, with a median dose of 60 GyRBE in 30 fractions. Initial treatment response assessment showed complete (n = 1) or partial (n = 3) responses. Limited toxicity was observed, primarily grade 2 alopecia and one case of radiation necrosis graded at 2. This early experience demonstrates the feasibility of TMPPR delivery, highlighting the importance of prospective evaluations in the re-irradiation setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI